Tag Archives: ISPOR

A global discussion on health care policy and innovation

Health care systems across the globe are as dynamic and complex as the populations they serve. Yet as varied as they are, they encounter common challenges as they strive toward the same goal — establishing and maintaining effective, affordable health care for their constituents. Last month, global experts and stakeholders convened to address some of […]
Read More »

ISPOR Asia-Pacific: Uniting to Create Impactful Change

Life sciences researchers, thought leaders and industry colleagues gathered in Singapore in early September to discuss the status of pharmacoeconomics and outcomes research in the Asia-Pacific region. The 7th ISPOR Asia-Pacific conference presented an opportunity to concentrate on the issues particular to this unique and diverse part of the world in an effort to achieve […]
Read More »

Opportunity in Asia-Pacific: A time of growth and development in health care

In early September, more than 1,200 researchers, thought leaders and industry colleagues will gather in beautiful Singapore to discuss the status of pharmacoeconomics and outcomes research in the Asia-Pacific region. The theme of the 7th ISPOR Asia-Pacific conference is Pharmacoeconomics and Outcomes Research in Asia-Pacific: Challenges, Opportunities, and Future Direction. This biennial conference has seen […]
Read More »

ISPOR Europe: Closing the gap between research and actionable outputs

Last month, thousands of global researchers, thought leaders and life sciences industry peers gathered in Italy for the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). We were all there in the name of health economics and outcomes research, which is very appropriate given that health economics was first […]
Read More »

A look back at the ISPOR Annual International Meeting

Last week, participants from across our enterprise gathered in Philadelphia to contribute to the 20th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference. ISPOR advances the policy, science, and practice of pharmacoeconomics (or health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being, including […]
Read More »

The Power of Real-World Evidence

Next week, May 16 – 20, Optum colleagues, clients, industry peers, global researchers and thought leaders are gathering in Philadelphia at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting. I’m looking forward to convening with our clients, discussing our progress and brainstorming about the new challenges to be tackled. Reflecting […]
Read More »

ISPOR Europe; A distinctive opportunity at the forefront of great change

In approximately 2 weeks, 3,800 global researchers and thought leaders will be coming together in Amsterdam to explore “New Challenges for Improving European Health Care” at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, November 8-12. The conference is a great opportunity for us to interface with clients, partners and […]
Read More »

ISPOR, Optum and the Power of Real-World Data

The life sciences industry is facing unprecedented opportunities and challenges, and I’m excited. We’re entering new and diverse markets, unlike any we’ve experienced before, while at the same time the dynamics in existing markets are becoming more complex due to health care transformation efforts.

CMS Quality Star Ratings Offer Opportunity for Adherence Evidence Generation

The Centers for Medicare & Medicaid Services’ (CMS) has implemented a five-star rating system for MedicareAdvantage and Part D health plans including measures of patient medication adherence for diabetes, hypertension and hypercholesterolemia. At the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, my colleagues and I discussed how these new adherence requirements […]
Read More »

What’s the “Best” Data?–The Data That Can Answer the Question!

In a previous post by my colleague Dr. Aylin Altan Riedel, she presented an overview of Analyze This!, an educational symposium sponsored by Optum Life Sciences at the 18th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting. I’m pleased to be a part of this panel discussion focused on getting the […]
Read More »